[
  {
    "ts": null,
    "headline": "Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data",
    "summary": "Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.",
    "url": "https://finnhub.io/api/news?id=b04b3774780828ba81eb524510bad86c795160c4f992c96d5c2822139bb18ea3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744661542,
      "headline": "Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data",
      "id": 133917760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.",
      "url": "https://finnhub.io/api/news?id=b04b3774780828ba81eb524510bad86c795160c4f992c96d5c2822139bb18ea3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries",
    "summary": "HYDERABAD (Reuters) -The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the medicine, according to a Reuters survey.  The survey of 18 doctors, patients and weight-loss clinic operators follows the U.S. drugmaker's market entry ahead of Danish obesity drug rival Novo Nordisk into a nation expected to have the second-largest population of overweight or obese people by 2050.  \"Since the launch of Mounjaro, we have seen a remarkable increase in customer interest,\" said Suryansh Kumar, founder of  Delhi-based weight management services provider Elevate Now.",
    "url": "https://finnhub.io/api/news?id=450d652520858735f81a4d297f612ffc79c85e22f258a971ce30b55295ee6c58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744660158,
      "headline": "Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries",
      "id": 133917761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HYDERABAD (Reuters) -The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the medicine, according to a Reuters survey.  The survey of 18 doctors, patients and weight-loss clinic operators follows the U.S. drugmaker's market entry ahead of Danish obesity drug rival Novo Nordisk into a nation expected to have the second-largest population of overweight or obese people by 2050.  \"Since the launch of Mounjaro, we have seen a remarkable increase in customer interest,\" said Suryansh Kumar, founder of  Delhi-based weight management services provider Elevate Now.",
      "url": "https://finnhub.io/api/news?id=450d652520858735f81a4d297f612ffc79c85e22f258a971ce30b55295ee6c58"
    }
  },
  {
    "ts": null,
    "headline": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
    "summary": "A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped Monday.",
    "url": "https://finnhub.io/api/news?id=f4af9b21894f4d18f143b903ad8c7a970803f2b6f71894c9c2e091fbab662792",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744651620,
      "headline": "This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.",
      "id": 133908182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A Verve Therapeutics treatment was found to cut cholesterol levels by more than half—with just one shot. The stock jumped Monday.",
      "url": "https://finnhub.io/api/news?id=f4af9b21894f4d18f143b903ad8c7a970803f2b6f71894c9c2e091fbab662792"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceutical Tariffs Coming Soon",
    "summary": "President Trump said Monday that he is going to impose new tariffs on pharmaceuticals soon.  “Pharmaceuticals we’re going to do,” he said.  Trump has been imposing tariffs as a way to entice companies to move manufacturing to the U.S., where they would avoid import levies.",
    "url": "https://finnhub.io/api/news?id=b8e531856838dad626d87521f3ef73e305236c7d155347b93f9f0c82a7ff9602",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744650804,
      "headline": "Pharmaceutical Tariffs Coming Soon",
      "id": 133908183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump said Monday that he is going to impose new tariffs on pharmaceuticals soon.  “Pharmaceuticals we’re going to do,” he said.  Trump has been imposing tariffs as a way to entice companies to move manufacturing to the U.S., where they would avoid import levies.",
      "url": "https://finnhub.io/api/news?id=b8e531856838dad626d87521f3ef73e305236c7d155347b93f9f0c82a7ff9602"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
    "summary": "Pfizer bows, but is not entirely out of the GLP-1 race.",
    "url": "https://finnhub.io/api/news?id=851c58dad62e8dbbdaef0f5e04a8dfcc1947e1558ed2bdb32422f56461152881",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744643550,
      "headline": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
      "id": 133908184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer bows, but is not entirely out of the GLP-1 race.",
      "url": "https://finnhub.io/api/news?id=851c58dad62e8dbbdaef0f5e04a8dfcc1947e1558ed2bdb32422f56461152881"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Monday: Apple, Palantir, Intel, Pfizer",
    "summary": "↗️ Goldman Sachs (GS): The Wall Street bank posted better-than-expected results, boosted by a surge in equities trading in the first quarter, which ended just before President Trump's sweeping tariffs disrupted markets.",
    "url": "https://finnhub.io/api/news?id=d063925936e070a53c8d84064e46db0f291eda787cc6f7b43ae5c1df118386d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744642595,
      "headline": "Stocks to Watch Monday: Apple, Palantir, Intel, Pfizer",
      "id": 133908153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Goldman Sachs (GS): The Wall Street bank posted better-than-expected results, boosted by a surge in equities trading in the first quarter, which ended just before President Trump's sweeping tariffs disrupted markets.",
      "url": "https://finnhub.io/api/news?id=d063925936e070a53c8d84064e46db0f291eda787cc6f7b43ae5c1df118386d8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer just had a big setback in its race for an Ozempic competitor",
    "summary": "Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.",
    "url": "https://finnhub.io/api/news?id=e6721c36b031d6e8fa68b50530014d04e365b3d68a2b6c88efb58a6fa90be43b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744642553,
      "headline": "Pfizer just had a big setback in its race for an Ozempic competitor",
      "id": 133908186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.",
      "url": "https://finnhub.io/api/news?id=e6721c36b031d6e8fa68b50530014d04e365b3d68a2b6c88efb58a6fa90be43b"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly and Company (LLY): “The Fastest Factory I’ve Ever Seen”",
    "summary": "We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other key stocks that Jim Cramer highlights. In his latest appearance on CNBC’s Squawk on the Street, Jim […]",
    "url": "https://finnhub.io/api/news?id=e4f02a7c63d7061b643b08d3ae46ee0c3eb92bf4f00ab92a79dc83b47351aebc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744641583,
      "headline": "Jim Cramer on Eli Lilly and Company (LLY): “The Fastest Factory I’ve Ever Seen”",
      "id": 133908187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other key stocks that Jim Cramer highlights. In his latest appearance on CNBC’s Squawk on the Street, Jim […]",
      "url": "https://finnhub.io/api/news?id=e4f02a7c63d7061b643b08d3ae46ee0c3eb92bf4f00ab92a79dc83b47351aebc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'",
    "summary": "Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial experienced a \"liver injury.\"",
    "url": "https://finnhub.io/api/news?id=5c8afc69eaf0029ebdd37b6594bc2f1ef0199d4be3dd6b099a64bee3888c56ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744640037,
      "headline": "Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'",
      "id": 133908188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial experienced a \"liver injury.\"",
      "url": "https://finnhub.io/api/news?id=5c8afc69eaf0029ebdd37b6594bc2f1ef0199d4be3dd6b099a64bee3888c56ae"
    }
  },
  {
    "ts": null,
    "headline": "Aristotle Large Cap Growth Q1 2025 Commentary",
    "summary": "For Q1 2025, Aristotle Atlanticâs Large Cap Growth Composite posted a total return of -9.55% gross of fees (-9.68% net of fees). Read more here.",
    "url": "https://finnhub.io/api/news?id=e906c48925d7c3a8d1cb7fb94d8acf9806858b2c1a5ee43a36f1dd79fd117e8a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744639740,
      "headline": "Aristotle Large Cap Growth Q1 2025 Commentary",
      "id": 133908929,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367307622/image_1367307622.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, Aristotle Atlanticâs Large Cap Growth Composite posted a total return of -9.55% gross of fees (-9.68% net of fees). Read more here.",
      "url": "https://finnhub.io/api/news?id=e906c48925d7c3a8d1cb7fb94d8acf9806858b2c1a5ee43a36f1dd79fd117e8a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
    "summary": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
    "url": "https://finnhub.io/api/news?id=812a7d5093c0afd44509f02ad0687ff7a2a655b8a4d67d85c678a45d2fcf07f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744638810,
      "headline": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
      "id": 133908189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
      "url": "https://finnhub.io/api/news?id=812a7d5093c0afd44509f02ad0687ff7a2a655b8a4d67d85c678a45d2fcf07f9"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
    "summary": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
    "url": "https://finnhub.io/api/news?id=4c211fe3a33603657009be603723bb1128bb751a760e4fc8bc372351ff13c347",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744638600,
      "headline": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
      "id": 133912117,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out",
      "url": "https://finnhub.io/api/news?id=4c211fe3a33603657009be603723bb1128bb751a760e4fc8bc372351ff13c347"
    }
  },
  {
    "ts": null,
    "headline": "Three Stocks That May Be Trading Below Their Estimated Value In April 2025",
    "summary": "Over the last 7 days, the United States market has risen by 5.8%, contributing to a 4.8% climb over the past year, with earnings forecasted to grow by 14% annually. In this environment of growth, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to capitalize on undervalued assets.",
    "url": "https://finnhub.io/api/news?id=dfad4f22fffaa07b14779cc94cc0ebfb4b434ce102eba9b0d875a6036d56d2d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744630675,
      "headline": "Three Stocks That May Be Trading Below Their Estimated Value In April 2025",
      "id": 133908190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Over the last 7 days, the United States market has risen by 5.8%, contributing to a 4.8% climb over the past year, with earnings forecasted to grow by 14% annually. In this environment of growth, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to capitalize on undervalued assets.",
      "url": "https://finnhub.io/api/news?id=dfad4f22fffaa07b14779cc94cc0ebfb4b434ce102eba9b0d875a6036d56d2d0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk.",
    "summary": "Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=b5868d921db2bc4188d11e999cd4a834669208c038c16403f931a83b30f352cc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744629300,
      "headline": "Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk.",
      "id": 134146424,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=b5868d921db2bc4188d11e999cd4a834669208c038c16403f931a83b30f352cc"
    }
  }
]